Data from a large prospective study identified male and older patients as being more likely to develop CIP and 34% of cases ...

Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI ...

A preliminary analysis of patient-reported outcomes for emotional functioning (EF) in patients with solid tumors revealed ...

Chemo-induced myelosuppression can affect patients’ ability to do daily tasks, and management varies by patient, treatment ...

On this episode of Onc Nurse On Call, Kristin Daly, MSN, ANP-BC, AOCNP, discusses practical cancer care strategies in the age ...

Panelists discuss how the phase 3 MK-3475-877 trial findings demonstrated subcutaneous pembrolizumab’s pharmacokinetic comparability to intravenous (IV) formulation with similar efficacy (45% vs 42% ...

Learn the critical factors in determining prophylaxis for venous thromboembolism, a frequent and serious complication for ...

Following imlunestrant’s approval, Komal Jhaveri, MD, FACP, compares the oral SERD to its counterpart, elacestrant, in terms of composition and trials.

AI-driven decision support can ease oncologists’ workloads and streamline care without reducing autonomy.

The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma ...